약물 순응 조현병 환자의 질병과 치료에 대한 태도: 질적 연구
Attitude Toward Illness and Treatment in Adherent Schizophrenia Patients: A Qualitative Study
0
조회
0
다운로드
1
인용
0
참고문헌
초록
Objectives The adherence to antipsychotics is essential for relapse prevention in schizophrenia. Although 40–60% of schizophrenia patients suffer from non-adherence problems, some patients had consistently good adherence. They are clinically desirable examples of non-adherent patients. This qualitative study aimed to explore the actors influencing medication adherence in people with schizophrenia with good adherence to the patients’ perspectives. Methods In-depth semi-structured interviews were conducted with 23 subjects with schizophrenia. Narratives were elicited on the attitudes toward illness and treatment, familiar support for treatment, and perceived stigma about psychosis over time. Results In the process of changing from non-adherence to adherence, symptomatic relapse, involuntary treatment, and familial support played leading roles. The patients’ experiences on their own made them accept the illness and necessity of medications. Once the patients accepted the need for treatments, side effects and social stigma did not influence their adherence. Reducing psychotic symptoms was the priority of the treatment effects on the patients’ perspectives. Conclusion Adherence in schizophrenia requires multiple factors that affect the attitude toward illness and medication over time. Therefore, it is necessary to understand the specific process of adherence and develop the relevant interventions to facilitate those processes over time.
Abstract
Objectives The adherence to antipsychotics is essential for relapse prevention in schizophrenia. Although 40–60% of schizophrenia patients suffer from non-adherence problems, some patients had consistently good adherence. They are clinically desirable examples of non-adherent patients. This qualitative study aimed to explore the actors influencing medication adherence in people with schizophrenia with good adherence to the patients’ perspectives. Methods In-depth semi-structured interviews were conducted with 23 subjects with schizophrenia. Narratives were elicited on the attitudes toward illness and treatment, familiar support for treatment, and perceived stigma about psychosis over time. Results In the process of changing from non-adherence to adherence, symptomatic relapse, involuntary treatment, and familial support played leading roles. The patients’ experiences on their own made them accept the illness and necessity of medications. Once the patients accepted the need for treatments, side effects and social stigma did not influence their adherence. Reducing psychotic symptoms was the priority of the treatment effects on the patients’ perspectives. Conclusion Adherence in schizophrenia requires multiple factors that affect the attitude toward illness and medication over time. Therefore, it is necessary to understand the specific process of adherence and develop the relevant interventions to facilitate those processes over time.
참고문헌 (27)
- Müller N, "Mechanisms of relapse prevention in schizophrenia", Pharmacopsychiatry, 37(Suppl 2), pp.S141~S147 (2004)
- Ascher-Svanum H, "Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care", J Clin Psychiatry, 67, pp.453~460 (2006)
- Novick D, "Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia", Psychiatry Res, 176, pp.109~113 (2010)
- Lacro JP, "Prevalence of and risk factors for medication nonadherence in patients with schizophrenia : a comprehensive review of recent literature", J Clin Psychiatry, 63, pp.892~909 (2002)
- Sendt KV, "A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders", Psychiatry Res, 225, pp.14~30 (2015)
- Valenstein M, "Antipsychotic adherence over time among patients receiving treatment for schizophrenia : a retrospective review", J Clin Psychiatry, 67, pp.1542~1550 (2006)
- Hardeman SM, "Simplifying adherence in schizophrenia", Psychiatr Serv, 61, pp.405~408 (2010)
- Davidson L, "Using qualitative research to inform mental health policy", Can J Psychiatry, 53, pp.137~144 (2008)
- Rogers A, "The meaning and management of neuroleptic medication : a study of patients with a diagnosis of schizophrenia", Soc Sci Med, 47, pp.1313~1323 (1998)
- Kikkert MJ, "Medication adherence in schizophrenia: exploring patients’, carers’ and professionals’ views", Schizophr Bull, 32, pp.786~794 (2006)
- Tranulis C, "Becoming adherent to antipsychotics : a qualitative study of treatment-experienced schizophrenia patients", Psychiatr Serv, 62, pp.888~892 (2011)
- 강시현, "6개월 이상 추적진료 도중 입원한 정신분열병 환자의 입원 전 항정신병 약물 순응도 및 유지 용량", 대한정신약물학회지, 15(2), pp.186~195 (2004), 대한정신약물학회
- Hogan TP, "A self-report scale predictive of drug compliance in schizophrenics : reliability and discriminative validity", Psychol Med, 13, pp.177~183 (1983)
- 윤보현, "한국판 약물태도 척도의 심리측정적 특성", 대한정신약물학회지, 16(6), pp.480~487 (2005), 대한정신약물학회
- Martins MJRV, "Assessing beliefs and attitudes towards antipsychotic medication from a recovery-based perspective : psychometric properties of a new scale", Psychiatry Res, 273, pp.325~330 (2019)
- Birchwood M, "A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change", Acta Psychiatr Scand, 89, pp.62~67 (1994)
- 7Kim JH, "Assessing the reliability and validity of the Korean version of the revised Insight Scale for Psychosis(KISP)", Korean J Schizophr Res, 17, pp.15~22 (2004)
- Acosta FJ, "Medication adherence in schizophrenia", World J Psychiatry, 2, pp.74~82 (2012)
- Day JC, "Attitudes toward antipsychotic medication : the impact of clinical variables and relationships with health professionals", Arch Gen Psychiatry, 62, pp.717~724 (2005)
- Blackwell B, "From compliance to alliance. A quarter century of research", Neth J Med, 48, pp.140~149 (1996)
- Ayyagari R, "Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders", J Med Econ, 23, pp.204~212 (2020)
- Lipkovich I, "Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy", J Psychiatr Res, 41, pp.305~310 (2007)
- Glick ID, "Should antipsychotic medications for schizophrenia be given for a lifetime?: a naturalistic, long-term follow-up study", J Clin Psychopharmacol, 37, pp.125~130 (2017)
- Baloush-Kleinman V, "Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study", Schizophr Res, 130, pp.176~181 (2011)
- Alvarez-Jimenez M, "Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies", Schizophr Res, 139, pp.116~128 (2012)
- Hui CL, "Detection of non-adherent behaviour in early psychosis", Aust N Z J Psychiatry, 40, pp.446~451 (2006)
- Hudson TJ, "A pilot study of barriers to medication adherence in schizophrenia", J Clin Psychiatry, 65, pp.211~216 (2004)